Financial Contrast: Rapid Micro Biosystems (NASDAQ:RPID) versus DarioHealth (NASDAQ:DRIO)

Rapid Micro Biosystems (NASDAQ:RPID) and DarioHealth (NASDAQ:DRIO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, earnings, risk and analyst recommendations.

Institutional & Insider Ownership

52.6% of Rapid Micro Biosystems shares are owned by institutional investors. Comparatively, 33.4% of DarioHealth shares are owned by institutional investors. 12.7% of Rapid Micro Biosystems shares are owned by company insiders. Comparatively, 3.5% of DarioHealth shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations for Rapid Micro Biosystems and DarioHealth, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rapid Micro Biosystems	1	0	1	0	2.00
DarioHealth	1	1	2	0	2.25

Rapid Micro Biosystems presently has a consensus price target of $8.00, indicating a potential upside of 308.16%. DarioHealth has a consensus price target of $27.00, indicating a potential upside of 223.35%. Given Rapid Micro Biosystems’ higher possible upside, equities research analysts plainly believe Rapid Micro Biosystems is more favorable than DarioHealth.

Profitability

This table compares Rapid Micro Biosystems and DarioHealth’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Rapid Micro Biosystems	-145.81%	-113.87%	-64.05%
DarioHealth	-192.23%	-60.52%	-37.08%

Valuation & Earnings

This table compares Rapid Micro Biosystems and DarioHealth”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rapid Micro Biosystems	$34.38 million	2.59	-$47.12 million	($1.12)	-1.75
DarioHealth	$22.36 million	2.73	-$41.71 million	($8.88)	-0.94

DarioHealth has lower revenue, but higher earnings than Rapid Micro Biosystems. Rapid Micro Biosystems is trading at a lower price-to-earnings ratio than DarioHealth, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Rapid Micro Biosystems has a beta of 1.52, meaning that its share price is 52% more volatile than the S&P 500. Comparatively, DarioHealth has a beta of 1.09, meaning that its share price is 9% more volatile than the S&P 500.

About Rapid Micro Biosystems

Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in the United States, Germany, Switzerland, Japan, and internationally. The company offers Growth Direct platform, which includes Growth Direct system, proprietary consumables, lab information management system connection software, and customer support and validation services. Its platform automates and modernizes the manual microbial quality control (MQC) testing workflows for therapeutic modalities, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company also provides onsite technical training services. Its solutions are used in environmental monitoring, water, bioburden, and sterility release testing applications. In addition, the company offers RMBNucleus software for the Growth Direct system; RMBNucleus Mold Alarm signals at the first sign of mold detection; RMBNucleus Central Manager portal streamlines coordination of multiple instruments; and Growth Direct LIMS connection software. Rapid Micro Biosystems, Inc. was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. in January 2007. The company was incorporated in 2006 and is headquartered in Lowell, Massachusetts.

About DarioHealth

DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such as diabetes, pre-diabetes, hypertension, and weight management; Dario Move, which address most common musculoskeletal conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; and Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems. It also provides native devices, such as glucose meter, blood pressure cuff, digital scale, and biofeedback sensor device, as well as live coaching services. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.